Pharmaceutical Care in Viral Diseases (HIV and Hepatitis C)

  • Susan KamalEmail author
  • Olivier Bugnon
  • Marie-Paule Schneider


Pharmacists are well positioned within the care continuum to help patients achieve their treatment outcomes as they are easily accessible, are in contact with the patients when they visit the pharmacy at treatment initiation and overtime for refill visits, and they have education and training in the management of drug–drug interactions and adverse effects. In this chapter, we highlighted evidence-based pharmaceutical care interventions in adherence, which is an important DRP in HIV and hepatitis C infections.


Pharmaceutical Care AIDS Hepatitis Prevention Medication adherence 


  1. 1.
    HIV/AIDS JUNPo. Global AIDS update 2016. Geneva: UNAIDS;2016.Google Scholar
  2. 2.
    Organization WH. Global hepatitis report 2017: executive summary;2017.Google Scholar
  3. 3.
    Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47.CrossRefGoogle Scholar
  4. 4.
    Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefGoogle Scholar
  5. 5.
    IDSA Aa. HCV Guidance: recommendations for testing, managing, and treating Hepatitis C [Available from:
  6. 6.
    EACS. European treatment guidelines [Available from:
  7. 7.
    Liver SAftsot. SASL-SSI Expert opinion statement on the treatment of Chronic Hepatitis C—August 2017 Update [Available from:
  8. 8.
    Liverpool Uo. HIV Drug interaction checker [Available from:
  9. 9.
    Liverpool Uo. [Available from:
  10. 10.
    Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hep Intl. 2016;10(2):310–9.CrossRefGoogle Scholar
  11. 11.
    Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist’s interventions. AIDS Care. 2010;22(10):1189–94.CrossRefGoogle Scholar
  12. 12.
    March K, Mak M, Louie SG. Effects of pharmacists’ interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm. 2007;64(24):2574–8.CrossRefGoogle Scholar
  13. 13.
    Henderson KC, Hindman J, Johnson SC, Valuck RJ, Kiser JJ. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. Aids Patient Care STDS. 2011;25(4):221–8.CrossRefGoogle Scholar
  14. 14.
    Horberg MA, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(5):531–9.CrossRefGoogle Scholar
  15. 15.
    Scott J, Abernathy K, Diaz-Linares M, Graham K, Lee J. HIV clinical pharmacists–the US perspective. Farmacia Hospitalaria. 2010;34(6):303–8.CrossRefGoogle Scholar
  16. 16.
    McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12(4):399–404.CrossRefGoogle Scholar
  17. 17.
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.CrossRefGoogle Scholar
  18. 18.
    Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M, Canete N, Cirera I, Coll S, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol. 2013;59(5):926–33.CrossRefGoogle Scholar
  19. 19.
    Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm. 2014;20(6):533–40.Google Scholar
  20. 20.
    Lelubre M, Kamal S, Genre N, Celio J, Gorgerat S, Hugentobler Hampai D, et al. Interdisciplinary medication adherence program: the example of a University Community Pharmacy in Switzerland. BioMed Research International. 2015;2015:ID 103546.CrossRefGoogle Scholar
  21. 21.
    Kamal S, Glass TR, Calmy A, Lecompte MT, Bugnon O, Parienti J-J, et al. 145-Does an adherence-enhancing program increase retention in care in the Swiss HIV Cohort? IAPAC; 06.06.2017; Miami, USA;2017.Google Scholar
  22. 22.
    Castillo E, Palepu A, Beardsell A, Akagi L, Yip B, Montaner J, et al. Outpatient pharmacy care and HIV viral load response among patients on HAART. AIDS Care. 2004;16(4):446–57.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Susan Kamal
    • 1
    Email author
  • Olivier Bugnon
    • 1
  • Marie-Paule Schneider
    • 1
  1. 1.University of Geneva and University of LausanneLausanneSwitzerland

Personalised recommendations